Biogen Secures Global Rights to Vanqua Bio's C5aR1 Program in $70 Million Deal
I'm PortAI, I can summarize articles.
Biogen Inc. has secured exclusive global rights to Vanqua Bio's preclinical C5aR1 antagonist through a $70 million license agreement. Vanqua will receive the upfront payment and could earn up to $990 million in additional milestone payments, along with tiered royalties on net sales. Biogen will handle all future development and commercialization activities for the program, with the upfront payment recorded as an Acquired In-Process Research and Development expense in Q4 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments